Scholar Rock Announces Completion Of Enrollment For The Phase 3 SAPPHIRE Trial; Topline Data From Phase 3 Trial Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock (NASDAQ:SRRK) has completed enrollment for the Phase 3 SAPPHIRE trial, which is evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA). The company also plans to present encore data from its Phase 2 TOPAZ trial extension period at the 2023 World Muscle Society (WMS) Annual Congress. Topline data from the Phase 3 trial is expected in Q4 2024.
September 19, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scholar Rock's completion of enrollment for the Phase 3 SAPPHIRE trial and the upcoming presentation of Phase 2 TOPAZ trial data could potentially boost investor confidence in the company's progress and its drug candidate, apitegromab.
The completion of enrollment for the Phase 3 SAPPHIRE trial indicates progress in the company's clinical development program. The upcoming presentation of Phase 2 TOPAZ trial data could provide further evidence of apitegromab's potential efficacy, which could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100